Selskabets formål er : (a) at importere/eksportere, registrere, markedsføre og distribuere lægemidler og relaterede produkter til brug for mennesker eller dyr, (b) at stifte, have andel i, administrere, rådgive, auditere, samarbejde med, forestå ledelsen af og yde tjenester til andre selskaber og virksomheder, samt finansiere andre selskaber og virksomheder, og (c) at udføre enhver aktivitet, som måtte være relateret til eller befordrende for ovenstående i bredest mulige forstand. Selskabet kan stille sikkerhed, pantsætte aktiver, garantere for opfyldelsen af samt forpligte sig særskilt eller på anden vis for betalingen af koncernselskabers og/eller tredjemands gæld.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 632.2 mio. | 57.4 mio. | 325.7 mio. | 166.9 mio. | 37 | |
CVR: 29634076
Secondary names: TEVA NORDIC A/S, Actavis Nordic A/S, 2K Pharma A/S
Compared to 405 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Companies in the same industry and area
CVR 26400260
CVR 40504044
CVR 37940844
CVR 31412390
CVR 17281402
TEVA DENMARK A/S demonstrates a positive financial trajectory, with revenue increasing from 411.4 million DKK in 2022 to 632.2 million DKK in 2024, alongside a rise in profit from 41.2 million DKK to 57.4 million DKK over the same period. The company's equity has seen a decline from 209.4 million DKK in 2023 to 166.9 million DKK in 2024, which raises some concerns regarding its financial stability. Despite this, the significant growth in both revenue and profit indicates strong operational performance and a recovery from previous losses in 2020. Positioned within the wholesale trade of pharmaceuticals and healthcare products, TEVA Denmark appears to be strengthening its market presence, although careful monitoring of its equity and margins is advisable.
AI-generated summary
companydata.dk